110105-42-5

Basic information

• Product Name: PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE
• Synonyms: PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE;N-(Pyridin-4-yl)piperidine-3-carboxamide;N-4-pyridinyl-3-Piperidinecarboxamide
• CAS NO: 110105-42-5
• Molecular Formula: C11H15N3O
• Molecular Weight: 205.26
• Mol File: 110105-42-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 439.855 °C at 760 mmHg
• Flash Point: 219.817 °C
• Appearance: /
• Density: 1.178 g/cm³
• PKA: 13.34±0.20(Predicted)
• CAS DataBase Reference: PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE(110105-42-5)
• EPA Substance Registry System: PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE(110105-42-5)

Safety Data

• Hazardous Substances Data: 110105-42-5(Hazardous Substances Data)

Usage

General Description

PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE is a chemical compound consisting of a piperidine ring with a carboxylic acid group at the 3-position and a pyridin-4-ylamide group. It is commonly used as a building block in the synthesis of pharmaceutical compounds and agrochemicals. PIPERIDINE-3-CARBOXYLIC ACID PYRIDIN-4-YLAMIDE has been studied for its potential applications in drug discovery and development due to its ability to interact with biological targets. It exhibits diverse pharmacological activities such as antiviral, anticancer, and anti-inflammatory properties, making it a valuable candidate for further research and development efforts in the pharmaceutical industry.

Relevant articles and documents

VISUAL FUNCTION DISORDER IMPROVING AGENTS

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo?2,3-büpyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent

Antitumor effect potentiators

When used concurrently with an antitumor agent, a compound having a Rho kinase inhibitory activity, such as (R)-(+)-N-(4-pyridyl)-4-(1-aminoethyl)benzamide, reinforces an antitumor effect of the antitumor agent and is useful as an antitumor effect potentiator. Particularly, a compound having a Rho kinase inhibitory activity used with an antitumor agent in combination can reduce the dose of the antitumor agent, which in turn affords provision of a sufficient effect and/or reduction of side effects.

PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS

An agent for the prophylaxis and treatment of vascular constriction is provided, which contains a compound having a Rho kinase inhibitory activity. In particular, a compound having a Rho kinase inhibitory activity, for example, (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, suppresses regenerative intima proliferation after disorder of blood vessel and has various other actions. Therefore, it is useful as an agent for the prophylaxis and treatment of vascular constriction, specifically, an agent for the prophylaxis and treatment of vascular constriction induced by disorder of vascular wall, such as vascular restenosis that occurs after an operation of percutaneus transluminal coronary angioplasty, vascular restenosis that occurs after an operation of percutaneus transluminal angioplasty, vascular constriction that occurs after vascular reconstruction, such as DCA, operation of intravascular indwelling of stent and the like, and vascular constriction that occurs after organ transplantation.